Test Catalog

Test Id : MEASU

Measles Virus, Molecular Detection, PCR, Urine

Useful For
Suggests clinical disorders or settings where the test may be helpful

Identifying measles infection using random urine specimens

Method Name
A short description of the method used to perform the test

Real-Time Polymerase Chain Reaction (PCR)

NY State Available
Indicates the status of NY State approval and if the test is orderable for NY State clients.

Yes

Reporting Name
Lists a shorter or abbreviated version of the Published Name for a test

Measles Virus PCR, Urine

Aliases
Lists additional common names for a test, as an aid in searching

MEASU

Measles virus

Measles

Rubeola

Specimen Type
Describes the specimen type validated for testing

Urine

Ordering Guidance

Polymerase chain reaction testing (this test) is recommended as the first-line test if a patient has symptoms of measles (ie, cough, fever, conjunctivitis, rash).

 

If serology has been performed and IgM-class antibodies against measles are detected (ROGM / Measles (Rubeola) Virus Antibody, IgM and IgG, Serum), this test should be ordered to confirm measles infection.

Shipping Instructions

Specimens must be shipped at refrigerated temperature. Specimens received frozen will be rejected.

Specimen Required
Defines the optimal specimen required to perform the test and the preferred volume to complete testing

Supplies: Urine Tubes, 10 mL (T068)

Container/Tube: Plastic, 10-mL urine tube

Specimen Volume: 1 mL

Collection Instructions:

1. Collect a random urine specimen.

2. No preservative

Specimen Minimum Volume
Defines the amount of sample necessary to provide a clinically relevant result as determined by the Testing Laboratory

0.3 mL

Reject Due To
Identifies specimen types and conditions that may cause the specimen to be rejected

Samples that have been heat inactivated
Urine containing preservatives
Reject

Specimen Stability Information
Provides a description of the temperatures required to transport a specimen to the performing laboratory, alternate acceptable temperatures are also included

Specimen Type Temperature Time Special Container
Urine Refrigerated 7 days

Useful For
Suggests clinical disorders or settings where the test may be helpful

Identifying measles infection using random urine specimens

Clinical Information
Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

Measles virus is a single-stranded, negative-sense RNA paramyxovirus belonging to the genus Morbillivirus that causes acute respiratory illness. Symptoms of infection include fever, malaise, cough, coryza, and conjunctivitis. Following the onset of symptoms, individuals typically develop a pathognomonic enanthema (Koplik spots) followed by a maculopapular rash. Measles virus is transmitted via inhalation of aerosols or respiratory droplets and is highly contagious. Measles virus can also be transmitted by direct contact with infected secretions or contaminated fomites. Laboratory confirmation of measles cases can be through serologic detection of measles-specific IgM antibodies or molecular detection of measles virus RNA. The use of reverse-transcription polymerase chain reaction can provide increased sensitivity and specificity compared to serologic testing if specimens are collected early after rash onset. Collection of both respiratory and urine samples for analysis is recommended to increase the likelihood of detecting the virus.

Reference Values
Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.

Negative

Interpretation
Provides information to assist in interpretation of the test results

A positive result indicates the presence of measles virus RNA in the specimen.

Cautions
Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

A negative test does not rule out infection with measles virus. Therefore, the results should be used in conjunction with clinical findings and serologic test results to make an accurate diagnosis.

 

The potential for false-negative results exists due to improper sample collection or viral variants.

Supportive Data

The following validation data support the use of this assay for clinical testing.

 

Accuracy:

Accuracy studies were performed by testing negative and positive (near the limit of detection) urine and upper respiratory swab samples. Urine yielded 88% positive agreement and 100% negative agreement with expected results. Upper respiratory swabs yielded 100% positive and 100% negative agreement with expected results.

 

Analytical Sensitivity/Limit of Detection:

The lower limit of detection of this assay is 2 genome copies/mcL for urine and 1 copy/mcL for throat swabs.

 

Precision:

Inter-assay and intra-assay precisions were 100%.

 

Specificity:

No sequences were identified that would result in cross-reactivity with the assay by in silico analysis. No cross-reactivity was detected in experiments testing a panel of nucleic acid extracts from greater than50 bacterial, fungal, and viral organisms causing similar disease or commonly found in urine or throat swabs.

 

Reportable Range:

This is a qualitative assay, and the results are reported as either "negative" or "positive" for the measles virus target.

Clinical Reference
Recommendations for in-depth reading of a clinical nature

1. Centers for Disease Control and Prevention (CDC) Measles (Rubeola): For Healthcare Providers. CDC. Updated November 5, 2020. Accessed September 7, 2022. Available at: www.cdc.gov/measles/hcp

2. Moss WJ. Measles. Lancet. 2017;390(10111):2490-2502.

3. Porter A, Goldfarb J. Measles: A dangerous vaccine-preventable disease returns. Cleve Clin J Med. 2019;86(6):393-398.

Method Description
Describes how the test is performed and provides a method-specific reference

The measles virus laboratory-developed reverse-transcription polymerase chain reaction (RT-PCR) assay is designed for the qualitative detection of measles virus RNA from urine and throat swabs of patients with suspected infection. Measles virus RNA in clinical specimens is first extracted using the NucliSENS easyMag/EMAG bioMerieux instruments according to manufacturer instructions. As a component of extraction, a lysis buffer is first added to clinical specimens in a class II biosafety cabinet (BSC). At this step, any measles virus that may be present in the sample is inactivated, rendering it non-infectious. Following the addition of lysis buffer, specimens are safe to remove from the BSC and placed onto an instrument for automated extraction. A sample input of 200 mcL will be extracted with an elution volume of 50 mcL.

 

This assay employs a reverse transcription reaction to convert RNA to complementary DNA. Oligonucleotide forward and reverse primers specific to the nucleoprotein (N) gene region of the measles virus amplify the target sequence. A TaqMan probe labeled with the fluorophore FAM and specific to the target region of measles virus RNA binds to amplified measles RNA virus product. Ribonuclease P (RNase P) is used as an internal control. Oligonucleotide forward and reverse primers specific to the p30 subunit of RNase P amplify the internal control target sequence. A TaqMan probe labeled with fluorophore Cy5 and specific to RNase P bind to the amplified RNase P product. The dye-labeled TaqMan probes allow for the detection of the target and internal control in the corresponding channels of the Roche LightCycler 480 II (LC480) instrument. Detection of the target N gene region indicates the presence of measles virus RNA in the specimen. The clinical validity of RT-PCR for the detection of the N gene of measles virus RNA in urine and throat swabs is well documented in peer-reviewed literature.(Unpublished Mayo method)

PDF Report
Indicates whether the report includes an additional document with charts, images or other enriched information

No

Day(s) Performed
Outlines the days the test is performed. This field reflects the day that the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time before the test is performed. Some tests are listed as continuously performed, which means that assays are performed multiple times during the day.

Monday through Friday

Report Available
The interval of time (receipt of sample at Mayo Clinic Laboratories to results available) taking into account standard setup days and weekends. The first day is the time that it typically takes for a result to be available. The last day is the time it might take, accounting for any necessary repeated testing.

1 to 3 days

Specimen Retention Time
Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded

1 week

Performing Laboratory Location
Indicates the location of the laboratory that performs the test

Rochester

Fees
Several factors determine the fee charged to perform a test. Contact your U.S. or International Regional Manager for information about establishing a fee schedule or to learn more about resources to optimize test selection.

  • Authorized users can sign in to Test Prices for detailed fee information.
  • Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
  • Prospective clients should contact their account representative. For assistance, contact Customer Service.

Test Classification
Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR) product.

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information
Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Clinic Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.

CPT codes are provided by the performing laboratory.

87798

LOINC® Information
Provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the order and results codes of this test. LOINC values are provided by the performing laboratory.

Test Id Test Order Name Order LOINC Value
MEASU Measles Virus PCR, Urine 86577-4
Result Id Test Result Name Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
617822 Measles Virus PCR, Urine 86577-4

Test Setup Resources

Setup Files
Test setup information contains test file definition details to support order and result interfacing between Mayo Clinic Laboratories and your Laboratory Information System.

Excel | PHP Pdf | CMS Pdf

Sample Reports
Normal and Abnormal sample reports are provided as references for report appearance.

Normal Reports | Abnormal Reports

SI Sample Reports
International System (SI) of Unit reports are provided for a limited number of tests. These reports are intended for international account use and are only available through MayoLINK accounts that have been defined to receive them.

SI Normal Reports | SI Abnormal Reports